These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9408441)

  • 1. Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure.
    Massy ZA; Guijarro C; O'Donnell MP; Kasiske BL; Keane WF
    Adv Nephrol Necker Hosp; 1997; 27():39-56. PubMed ID: 9408441
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipids and progressive renal failure.
    Keane WF
    Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.
    Joyce M; Kelly C; Winter D; Chen G; Leahy A; Bouchier-Hayes D
    J Surg Res; 2001 Nov; 101(1):79-84. PubMed ID: 11676559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids and renal disease.
    Trevisan R; Dodesini AR; Lepore G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S145-7. PubMed ID: 16565240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor from Pueraria thunbergiana.
    Kim HJ; Lee DH; Hwang YY; Lee KS; Lee JS
    J Agric Food Chem; 2005 Jul; 53(15):5882-8. PubMed ID: 16028969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Adam O; Neuberger HR; Böhm M; Laufs U
    Circulation; 2008 Sep; 118(12):1285-93. PubMed ID: 18794401
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids in progression of renal disease.
    Oda H; Keane WF
    Kidney Int Suppl; 1997 Nov; 62():S36-8. PubMed ID: 9350676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
    Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitory effect of Vitis vinifera.
    Koo M; Kim SH; Lee N; Yoo MY; Ryu SY; Kwon DY; Kim YS
    Fitoterapia; 2008 Apr; 79(3):204-6. PubMed ID: 18191910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
    Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
    Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipids and progressive renal disease: the cardio-renal link.
    Keane WF
    Am J Kidney Dis; 1999 Aug; 34(2):xliii-xlvi. PubMed ID: 10465726
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase does not inhibit the platelet procoagulant response.
    Lindhout T; Wielders S; Hamulyak K; Bevers E; ten Cate H
    J Thromb Haemost; 2008 Aug; 6(8):1424-6. PubMed ID: 18485079
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pleiotropic effect of statins in preventing progression of chronic renal disease].
    Chrzanowski W
    Pol Arch Med Wewn; 2003 Oct; 110(4):1181-3. PubMed ID: 14699677
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Istvan ES
    Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase lower fecundity in the German cockroach: correlation between the effects on fecundity in vivo with the inhibition of enzymatic activity in embryo cells.
    Zapata R; Piulachs MD; Bellés X
    Pest Manag Sci; 2003 Oct; 59(10):1111-7. PubMed ID: 14561068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia and the risk of end stage renal disease.
    Haydar AA; Goldsmith DJ
    J Med Liban; 2004; 52(3):156-9. PubMed ID: 16432973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.